arrow
C

Cynthia Behling

Rady Children's Hospital San Diego
H指数:47
被引数:2.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Vibration-controlled transient elastography in pediatric metabolic dysfunction-associated steatotic liver disease

振动控制瞬时弹性成像在儿童代谢功能障碍相关脂肪性肝病中的应用

2025-12-010
OAAI
Consensus position statements for the standardized application of histological grading and staging systems in MASH clinical trials

关于MASH临床试验中组织学分级和分期系统标准化应用的一致性立场声明

2025-10-080
PRE
Reclassifying pediatric NAFLD using the steatotic liver disease framework: A multicenter retrospective study from the NASH CRN

使用脂肪性肝病框架对儿科NAFLD进行重新分类:一项来自NASH CRN的多中心回顾性研究

2025-10-010
PRE
Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial

代谢功能障碍相关脂肪性肝炎(HARMONY)中,每周一次efruxifermin相较于安慰剂的疗效与安全性:一项多中心、随机、双盲、安慰剂对照、2b期试验的96周结果

2025-08-140
PRE
MASLD in people with HIV exhibits higher fibrosis stage despite lower disease activity than in matched controls
2024-09-050
OAAI
Review article: New developments in biomarkers and clinical drug development in alpha-1 antitrypsin deficiency-related liver disease
2024-03-222
PRE
Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo- controlled, phase 2b trial
2023-12-0144
PRE
Using a Proteomics-Based Cardiovascular Risk Test to Identify Systemic Changes in a Clinical Trial of Nonalcoholic Fatty Liver Disease

使用基于蛋白质组学的心血管风险测试来确定非酒精性脂肪性肝病临床试验中的系统性变化

2023-11-070
PRE
Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis

循环生物标志物对非酒精性脂肪性肝炎的诊断性能

2023-09-0737
OAAI